Stocks
Fennec Pharmaceuticals Inc.FENC
NASDAQHealthcareBiotechnology$10.08
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company focused on developing and commercializing sodium thiosulfate for the prevention of cisplatin-induced hearing loss in pediatric patients. Its sole marketed product, Pedmark, received FDA approval in 2022, making it a key player in the oncology supportive care space. Investors track Fennec for its niche market position and the commercial ramp of its first approved therapy.
52W Range: $5.65-$13.25
Congressional Interest in Fennec Pharmaceuticals Inc. (FENC)
No congressional trades have been disclosed for Fennec Pharmaceuticals Inc. (FENC) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading FENC?
No congressional trades found for this stock.